Esteban Domínguez Cerezo, MS, Science Writer —

A first group of healthy adults has been dosed in a Phase 1 safety and tolerability trial of Lucid-21-302, a potential myelin-protective oral treatment for multiple sclerosis (MS), regardless of disease type. These initial volunteers will serve as the trial’s sentinels, an occasional study feature allowing for a…

SetPoint Medical is planning to launch a clinical trial next year to investigate its nerve stimulator device, intending to support myelin repair, in people with relapsing-remitting multiple sclerosis (RRMS). The announcement comes after U.S. Food and Drug Administration (FDA) approval of an investigational device exemption, allowing the…

Plasma exchange (PLEX) therapy is effective for severe relapses in people with multiple sclerosis (MS) who respond inadequately to standard corticosteroid therapy, according to a new study conducted in Serbia. Better outcomes were seen in younger patients and in those with low disability scores at the time of…

Having antibodies against the rubella virus is associated with an increased risk of developing multiple sclerosis (MS) in unvaccinated people, a Swedish study suggests. The findings show a rubella infection may be a risk factor for MS, reinforcing the hypothesis that certain viral infections may trigger the misleading immune…

A potential treatment of relapsing-remitting multiple sclerosis (RRMS), arsenic trioxide (ATO) has been patented in the European Union based on findings in preclinical studies. Notice of an intent to grant patent EP18722530, titled “Method for treating relapsing-remitting multiple sclerosis using arsenic trioxide,” was given by the European Patent…

A grant from the National Institutes of Health (NIH) is supporting a U.S. study into the physical, cognitive, and psychological responses that may underlie a fear of falling in people with multiple sclerosis (MS). Specifically, the $96,812 two-year grant by the agency’s Eunice Kennedy Shriver National Institute of Child…

TG Therapeutics plans to soon launch a Phase 1 clinical trial to investigate the CAR T-cell therapy azercabtagene zapreleucel, or azer-cel, in people with progressive forms of multiple sclerosis (MS). The announcement comes after the U.S. Food and Drug Administration (FDA) cleared TG’s…

Indapta Therapeutics will launch a Phase 1 clinical trial in the U.S. in the second half of 2024 to explore its cell-based therapy IDP-023 in people with progressive forms of multiple sclerosis (MS). The announcement follows the U.S. Food and Drug Administration’s (FDA) clearance of the company’s investigational…

People with multiple sclerosis (MS) and other conditions who use Mallinckrodt‘s treatment Acthar Gel (repository corticotropin injection) now have a self-injection option, the company said. Acthar Gel Single-Dose Pre-filled SelfJect is available in two dosages — 40 USP units/0.5 ml and 80 USP units/1.0 mL — that…

Three innovative projects aimed at addressing unmet needs in multiple sclerosis (MS) and fostering new perspectives on the disease have received incubator grants from the nonprofit MS Australia. Totaling AU$74,813 (or about $48,700), the grants will support one-year projects that focus on MS social needs, disease biomarkers, and…